Spectrum (SPPI -3.1%) is at odds with Danish partner TopoTarget over the results of a Phase II...

|About: Spectrum Pharmaceuticals,... (SPPI)|By:, SA News Editor

Spectrum (SPPI -3.1%) is at odds with Danish partner TopoTarget over the results of a Phase II trial for their lymphoma drug belinostat. TopoTarget says the primary endpoint has been met, as the tumors in at least 20% of patients shrank. However, Spectrum is far more cautious, describing the results as "preliminary" and saying that the full outcome won't be known until all the data is analyzed. (PR)